Remy, C.; Caron, B.; Gouynou, C.; Haghnejad, V.; Jeanbert, E.; Netter, P.; Danese, S.; Peyrin-Biroulet, L.
Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. J. Clin. Med. 2022, 11, 7296.
https://doi.org/10.3390/jcm11247296
AMA Style
Remy C, Caron B, Gouynou C, Haghnejad V, Jeanbert E, Netter P, Danese S, Peyrin-Biroulet L.
Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of Clinical Medicine. 2022; 11(24):7296.
https://doi.org/10.3390/jcm11247296
Chicago/Turabian Style
Remy, Clotilde, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, and Laurent Peyrin-Biroulet.
2022. "Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience" Journal of Clinical Medicine 11, no. 24: 7296.
https://doi.org/10.3390/jcm11247296
APA Style
Remy, C., Caron, B., Gouynou, C., Haghnejad, V., Jeanbert, E., Netter, P., Danese, S., & Peyrin-Biroulet, L.
(2022). Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of Clinical Medicine, 11(24), 7296.
https://doi.org/10.3390/jcm11247296
